Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)

  Print   

Friday 09 July, 2021

Diurnal Group PLC

Director Dealings and Issue of Equity

RNS Number : 7455E
Diurnal Group PLC
09 July 2021
 

9 July 2021

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings and Issue of Equity

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the issue and allotment of 973,682 ordinary shares of £0.05 under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), including 679,768 new Shares to persons discharging managerial responsibilities ("PDMR").

 

PDMR  Total number of New  Nature of issuance

  Ordinary Shares issued 

Martin Whitaker  376,230  Vesting of deferred bonus award

Richard Bungay  225,738                                         Vesting of deferred bonus award

Richard Ross  77,800                                           Vesting of deferred bonus award

 

The shares were issued under the Company's Employee Benefit Trust scheme.

 

Martin Whitaker and Richard Bungay have informed the Company that they intend to sell sufficient shares to pay all or part of their personal tax liability arising from the vesting of their deferred bonus awards once the New Ordinary Shares have been admitted for trading on AIM and will retain the balance of shares. These transactions will be subject to a further RNS announcement in due course.

 

Following the issue of shares, the total beneficial interest of Martin Whitaker and his connected parties is 980,053 Ordinary Shares, representing 0.58% of the total voting rights, the total beneficial interest of Richard Bungay is 339,990 Ordinary Shares, representing 0.20% of the total voting rights, and the total beneficial interest of Richard Ross and his connected parties is 2,262,155 Ordinary Shares, representing 1.34% of the total voting rights.

 

Application has been made for admission of the 973,682 New Ordinary Shares to trading on AIM, which is anticipated to occur at 8:00am on Monday 12 July 2021 ("Admission"). The New Ordinary Shares will rank pari passu with the existing shares of common stock of the Company. Following Admission, the Company's issued ordinary share capital will consist of 168,903,690 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 168,903,690.

 

The above figure of 168,903,690 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

 

 

Identification code

GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil

376,230

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

As above

 

 

- Price

 

 

 

e)

 

Date of the transaction

 

9 July 2021

f)

 

Place of the transaction

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

 

 

Identification code

GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil

225,738

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

As above

 

 

- Price

 

 

 

e)

 

Date of the transaction

 

9 July 2021

f)

 

Place of the transaction

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Richard Ross

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Scientific Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

 

 

Identification code

GB00BDB6Q760

 

 

b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

Nil

77,800

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

As above

 

 

- Price

 

 

 

e)

 

Date of the transaction

 

9 July 2021

f)

 

Place of the transaction

 

XLON

 

For further information, please visit www.diurnal.co.uk or contact:

 

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

 

Richard Bungay, Chief Financial Officer

 

 

 

Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

 

Corporate Broking: Rupert Dearden

 

 

 

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

 

Victoria Foster Mitchell

 

 

 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFIFFDDIIAIIL

a d v e r t i s e m e n t